Dexamethasone

Generic Name
Dexamethasone
Brand Names
Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
Drug Type
Small Molecule
Chemical Formula
C22H29FO5
CAS Number
50-02-2
Unique Ingredient Identifier
7S5I7G3JQL
Background

Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
...

Indication

Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, an...

Associated Conditions
Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
Associated Therapies
-
Clinical Trials
Related News

LAssa Fever Adjunct Treatment With DEXamethasone

Phase 2
Not yet recruiting
Conditions
Lassa Fever
Interventions
Drug: Ribavirin
Drug: Dexamethasone
First Posted Date
2024-01-25
Last Posted Date
2024-01-25
Lead Sponsor
Bernhard Nocht Institute for Tropical Medicine
Target Recruit Count
42
Registration Number
NCT06222723

Iberdomide Vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

First Posted Date
2024-01-22
Last Posted Date
2024-10-18
Lead Sponsor
University of Heidelberg Medical Center
Target Recruit Count
411
Registration Number
NCT06216158
Locations
🇩🇪

Helios Klinikum Bad Saarow, Bad Saarow, Germany

🇩🇪

Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie, Berlin, Germany

🇩🇪

Helios Klinikum Berlin-Buch, Berlin, Germany

and more 50 locations

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

First Posted Date
2024-01-18
Last Posted Date
2024-05-17
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT06210750

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Phase 2
Not yet recruiting
Conditions
Lassa Fever
Interventions
Drug: Favipiravir
Drug: Ribavirin
Drug: Dexamethasone
First Posted Date
2024-01-18
Last Posted Date
2024-01-18
Lead Sponsor
Irrua Specialist Teaching Hospital
Target Recruit Count
1755
Registration Number
NCT06212336

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

First Posted Date
2024-01-17
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
795
Registration Number
NCT06208150
Locations
🇨🇳

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

🇨🇳

Tongji Hospital, Tongji Medical College of HUST, Wuhan, China

🇮🇱

Carmel Medical Center, Haifa, Israel

and more 192 locations

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

First Posted Date
2024-01-16
Last Posted Date
2024-05-14
Lead Sponsor
University of Chicago
Target Recruit Count
33
Registration Number
NCT06207123
Locations
🇺🇸

University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

First Posted Date
2024-01-16
Last Posted Date
2024-07-17
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
39
Registration Number
NCT06207305
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

First Posted Date
2024-01-12
Last Posted Date
2024-05-30
Lead Sponsor
Elvira Umyarova
Target Recruit Count
30
Registration Number
NCT06203912
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

First Posted Date
2024-01-05
Last Posted Date
2024-02-06
Lead Sponsor
Jin Lu, MD
Target Recruit Count
41
Registration Number
NCT06192979
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

First Posted Date
2024-01-05
Last Posted Date
2024-04-23
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
200
Registration Number
NCT06189833
Locations
🇬🇷

St Savvas Cancer Hospital, Athens, Greece

🇩🇪

Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany

🇦🇹

Innsbruck Medical University, Innsbruck, Austria

and more 28 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy